A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs INCB 59872 (Primary) ; Azacitidine; Nivolumab; Tretinoin
- Indications Acute myeloid leukaemia; Cancer; Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Incyte Corporation
- 08 Dec 2017 Planned number of patients changed from 180 to 215.
- 01 Nov 2017 Planned number of patients changed from 108 to 180.
- 01 Nov 2017 Planned End Date changed from 1 Apr 2018 to 1 Mar 2020.